ArticleJournal of ophthalmic inflammation and infection2026
Evaluation of safety and efficacy of cyclosporine-A eye drops in herpetic stromal keratitis: a prospective randomized clinical trial.
Article in Journal of ophthalmic inflammation and infection, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05720715 (Evaluation of the Safety and Efficacy of Cyclosporine A 0.05% Eye Drops in Management of Non- Necrotizing Herpetic Stromal Keratitis; a Prospective Controlled Clinical Trial), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Evaluation of the Safety and Efficacy of Cyclosporine A 0.05% Eye Drops in Management of Non- Necrotizing Herpetic Stromal Keratitis; a Prospective Controlled Clinical Trial
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo evaluate the additive effect of topical cyclosporine A (Cs-A) 0.05% eye drops with topical prednisolone compared with that of topical prednisolone acetate 1% eye drops alone for the treatment of herpetic stromal keratitis (HSK).
methodsPatients diagnosed with HSK were randomly divided into 2 groups: Group A received Cs-A eye drops b.i.d. with prednisolone eye drops q.i.d.; Group B received topical prednisolone q.i.d. with placebo eye drops b.i.d.; both Groups A & B received a systemic acyclovir therapeutic dose of 400 mg five times daily, tapered to twice daily on the 10th day. Follow-up was performed weekly for 2 months. The primary outcome measures included duration of treatment, corneal edema (CE), haziness (CH), punctate epitheliopathy (CP) and vascularization (CV). The secondary outcome measures included best corrected visual acuity (BCVA) and intraocular pressure (IOP).
resultsThirty eyes from 30 patients were included (15 in each group). At baseline, only the CP score was significantly greater in Group B. The duration of treatment was significantly shorter in Group A. At the 2-month follow-up, there were significant improvements in the CE, CH and CP scores in both groups compared with the baseline scores, but there were no significant differences between the groups. There was a significant improvement in BCVA in both groups compared with baseline scores, but there was no significant difference between the groups. Two patients in group B required topical drops to control the IOP.
conclusionThe addition of Cs-A eye drops to the treatment protocol for HSK patients has a significant role in shortening the duration of treatment in the management of HSK patients with and without epithelial ulceration. REGISTRATION: The study protocol was approved by the Local Review Board (Registration code: 2261), and ClinicalTrials.gov (ID: NCT05720715).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.